STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III TrialANTONY, France - Stallergenes S.A. has announced the first results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen and concerning the development of a sublingual immunotherapy tablet containing the recombinant allergen of this pollen, rBet v 1. Dornier Announces Premium Urological Workstation with Integrated LithotripsyMUNICH - Dornier is pleased to announce the addition of the Gemini to its product portfolio. The Gemini is a premium urological workstation with integrated lithotripsy, providing the best in class urological functionality. McGraw-Hill Medical Wins 2009 BMA Medical Book of the Year AwardLONDON - McGraw-Hill Medical won a number of honours and awards at the British Medical Association’s Medical Book Competition awards ceremony, including two category first prize awards and the contest’s top prize, Medical Book of the Year. The coveted award went to the ground-breaking Robotic Surgery: Theory and Operative Technique by Drs Farid Gharagozloo and Farzad Najam. Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling PathwayHEIDELBERG, Germany - - Integrated Chemical Genetics and Proteomics Approach Identifies new Potential Drug Targets in Wnt Pathway Forest Laboratories UK Ltd Submits Marketing Authorisation Application for the First Dry Powder Inhalation Antibiotic for Cystic Fibrosis PatientsLONDON - Forest Laboratories UK Ltd, (a wholly owned subsidiary of Forest Laboratories Inc) announced that following the successful completion of its pan-European multi-centre phase III study (the Freedom Study), it has applied to the European Medicines Evaluation Agency (EMEA) to licence its new formulation dry powder colistimethate sodium for inhalation (Colobreathe(R)) for use by Cystic Fibrosis patients. The new formulation which was wholly developed by Forest Laboratories UK has previously been granted orphan drug status by the European Medicines Evaluation Agency (EMEA) and when approved Colobreathe(R) will be made available throughout the EU in conjunction with its chosen partner Grünenthal GmbH. Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)KVISTGAARD, Denmark - Bavarian Nordic A/S (OMX: BAVA) announced today that it has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The vaccines will be delivered in 2009. The size and value of the contract is undisclosed. Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & SullivanCAPE TOWN, South Africa - Ghana’s healthcare industry is experiencing growth across a range of sectors. However, the drive towards improved diagnostic capability has led to high demand for medical imaging devices. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.FREISING-WEIHENSTEPHAN, Germany - Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris’ proprietary Anticalin technology with Allergan’s expertise in drug delivery and ophthalmic drug development with a goal of developing agents for the treatment of serious ocular disorders. Frost & Sullivan: First Responders’ Communication Interoperability - A Vital Need for Life-Saving ServicesLONDON - - Frost & Sullivan to Host Analyst Briefing on the C3I market on Tuesday, 22 September, 2009 at 14:00 BST 22nd ECNP Congress 2009: The Role of Genetic Factors in Adult ADHDISTANBUL - At the 22nd ECNP Congress, Dr. Barbara Franke, Radboud University Nijmegen Medical Centre, The Netherlands, presented today the latest findings in the identification of ADHD risk genes. “Converging evidence suggests that ADHD aetiology has a robust genetic component”, said Franke. Heritability of adult ADHD appears even higher than that in children: whereas a sibling of a child with ADHD has a 3-4-fold increased risk compared to control children, this risk-increase is 17-fold for a sibling of an adult ADHD patient. Major breakthroughs are expected from the International Multicenter persistent ADHD CollaboraTion (IMpACT), which is investigating the largest clinical ADHD sample worldwide. Early Administration of Aggrenox(R) is Effective and Safe After Acute Ischaemic Stroke or TIAINGELHEIM, Germany - - For Healthcare Media Outside the U.S.A., Canada, and Japan Early secondary prevention with Aggrenox(R) (extended-release dipyridamole [200 mg] plus ASA* [25mg]) is at least as effective and safe as initial treatment with ASA 100 mg alone after an ischaemic stroke or transient ischaemic attack (TIA). Results from the EARLY[1] study, presented for the first time at the 13th Congress of the European Federation of Neurological Societies in Florence on 15 September 2009, showed that while functional outcome at 3 months was similar between the two treatment groups there were numerically fewer recurrent ischaemic events in patients who received Aggrenox(R) from the first day after their ischaemic event compared to those patients who received ASA as initial therapy. Helsinn Partners With Eisai for Gelclair in ItalyLUGANO, Switzerland - The Swiss pharmaceutical group Helsinn and Eisai Italy, subsidiary of the Japanese pharmaceutical company, have signed a licensing agreement for the commercialization of the medical device Gelclair in Italy. Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with BazedoxifeneCOLLEGEVILLE, Pennsylvania - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis. These and other data were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Denver, Colo. Bazedoxifene, a selective estrogen receptor modulator (SERM), is under clinical investigation for the prevention and treatment of postmenopausal osteoporosis. All Roads Lead to Frost & Sullivan Excellence in Healthcare Awards BanquetLONDON - Frost & Sullivan will host its prestigious ‘Excellence in Healthcare Awards Banquet’ on Thursday, October 8, 2009, at the Guoman Charing Cross, London. Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009MENLO PARK, California - - European Commercial Pace Continues to Grow with 200 Patients Treated The End of the Sick DayANDOVER, England - Over half of people living in Britain are so scared of losing their job in the current climate that they are risking their health by working through illness. This is according to those surveyed as part of Simplyhealth’s Bothered Britain Report, which is released this month. The report investigates how attitudes and behaviour have changed in the past year towards health-related issues, as well as looking at what people are really bothered about at the moment. Patients Fear Osteoporosis Quality of Life Impact, Yet Lack Tools to Manage Concerns and Improve Osteoporosis Outcomes, New Survey SaysDENVER - - International Osteoporosis Foundation (IOF) launches OsteoLink to address unmet needs in osteoporosis management through digital and in-person patient and physician communication networks across Europe and Australia New Online Resource for People with Parkinson’s, Their Families and CarersFLORENCE, Italy - - Lundbeck and Teva Launch www.myPDinfo.com Lundbeck and Teva today announce the launch of www.myPDinfo.com to provide answers to common questions following a diagnosis of Parkinson’s disease. Designed for people with Parkinson’s, their families and carers, the new site provides information on the disease itself, as well as many aspects of treatment and practical disease management such as medication, surgery, diet, exercise/physiotherapy, and emotional support. 22nd ECNP Congress 2009: The Future of SchizophreniaISTANBUL - At the 22nd Congress of the European College of Neuropsychopharmacology (ECNP), Prof. William Carpenter from the Maryland Psychiatric Research Center, USA, gave today an outlook on a paradigm shift in schizophrenia research, which will have major influence on diagnosis and therapy. “In future schizophrenia research, the focus of therapeutic study will move away from schizophrenia as a disease entity onto specific domains of pathology, promoting the development of targeted drug therapies,” said Carpenter. “This may substantially improve the quality of life for patients in the near future, and prepare the field to address recovery, cure and prevention.” Novant Health Rolls Out MEDai’s Predictive Modeling Solution to Nine Hospitals in Three StatesORLANDO, Florida - - MEDai’s Pinpoint Review Clinical Surveillance System Will Help Novant Hospitals Ensure Patient Safety and Quality, Safeguard Hospital Reimbursement Important Step Forward in Osteoarthritis Research: Bioactive Collagen Peptides Stimulate the Regeneration of Cartilage TissueMONTREAL and KIEL, Germany - Working in collaboration with Kiel University, researchers at the Kiel- based Collagen Research Institute (CRI) have demonstrated the stimulating effect of special bioactive collagen peptides (FORTIGEL(R)) in the context of cell experiments. Last weekend the CRI presented its research findings at the congress of the Osteoarthritis Research Society International (OARSI) in Montreal. The investigations of the CRI provide an explanation for the findings of a joint clinical trial carried out by Harvard Medical School and Tufts Medical Center - likewise presented at the congress. With the aid of special imaging (MRI) techniques this clinical trial demonstrated that FORTIGEL(R) stimulated cell metabolism in the knee-joint cartilage and promotes the regeneration of cartilage tissue. Frost & Sullivan Finds the Untapped Patient Monitoring Solutions Market in Europe Offers Lucrative OpportunitiesLONDON - The market potential for patient monitoring solutions has largely remained untapped, while the demand that potentially exists is significant. Ageing baby boomers and the expansion of the middle class are the main drivers of the European patient monitoring market. Baby boomers are the leading consumers in healthcare by being more involved in the decision-making process on their treatment and overall health management. Moreover, the major impetus for physicians, hospitals and home health organisations to focus on monitoring their patients is cost. Fountain Healthy Aging Inc Announces Agreement to Acquire Natural Planet USALOS ANGELES - Fountain Healthy Aging Inc. announced on September 14 2009 that it had entered into an agreement to acquire the entire issued stock of Natural Planet USA Inc, a California based developer and distributor of a range of specialist nutraceutical and cosmoceutical products both in the US and across a range of international markets. Fountain has had a relationship with Natural Planet for some months, and has sourced a number of its key products from the Natural Planet product pipeline, as well as engaging Natural Planet as a non exclusive distributor of its flagship product, Vitalife, in the US. Dr M Group Selects Health Robotics’ Technology Over RIVA for all of its I.V. Compounding Centers in South East AsiaBOZEN, Italy - Health Robotics today reported that Dr M Group has selected the CytoCare(TM) and i.v.STATION(TM) Robots to be deployed across all of its I.V. Compounding Centers in Malaysia, Singapore, Indonesia, Vietnam, and India. Frost & Sullivan Honours Kemin Health With Global Weight Management Ingredients New Product Innovation AwardLONDON - The 2009 Frost & Sullivan Global Weight Management Ingredients New Product Innovation Award is presented to Kemin Health. Results of RebiSmart(TM) User Trial Presented at 25th ECTRIMS Congress Show Broad Patient Acceptance of the New Electronic Delivery Device for Relapsing Multiple Sclerosis Treatment Rebif(R)GENEVA - - The Majority of Patients Found the Electronic Multidose Device “Suitable” or “Very Suitable” for Self-Injection and Rated the Device Functions as “Easy” or “Very Easy” to Use 22nd ECNP Congress 2009: are the Monoamines Involved in Shaping Conduct Disorders?ISTANBUL, Turkey - New findings on the significance of platelet MAO activity and MAO gene variants with regard to antisocial behaviour have today been presented by Prof. Lars Oreland, University of Uppsala, Sweden, at a press conference during the 22nd ECNP Congress. Prof. Oreland outlined that, based on gene-environment interactions, the brain monoamine systems play a crucial role in shaping personality traits and conduct disorder. The monoamine oxidases (MAOs) genes appear to be the first genes strongly linked with either antisocial behaviour or conduct disorder. Medical Imaging Markets, Volume I - RadiographyMedical Imaging Markets, Volume I: Radiography (X-Ray, Digital X-Ray, Fluoroscopy, Mammography, and CT Markets) Report ( http://www.bharatbook.com/Market-Research-Reports/Medical-Imaging-Markets-Volume-I-Radiography-X-Ray-Digital-X-Ray-Fluoroscopy-Mammography-and-CT-Markets.html ) estimates that the reinvigorated market for medical imaging systems employing x-rays has undoubtedly been propelled by the explosion of digital technology. But also, the expanded role of imaging modalities in a whole host of clinical applications from trauma to cancer to cardiology has increased the profile of radiography while enabling computer technologies expand the usefulness of traditional x-ray techniques. Size and Growth for Medical Beds and Chairs MarketMedical Beds and Medical Chairs Report ( http://www.bharatbook.com/Market-Research-Reports/Medical-Beds-and-Medical-Chairs.html ) provides the reader with an overview of the medical beds and medical chairs industry and the trends driving growth. Medical beds include all hospital types of beds including mattresses and overlays. The term medical chairs can refer to many different types of chairs including ENT chairs, examination chairs, blood drawing chairs, cardiac chairs, dialysis chairs, ophthalmic chairs, surgery chairs and many more. For the purposes of this report, only rehabilitation chairs and wheelchairs are considered in the market coverage. Amnis advocates a strategic approach to ensuring NHS efficiencyAccording to the specialist healthcare quality, innovation and productivity improvement enabler, Amnis, there needs to be a fundamental shift in the way healthcare organisations work, both internally and across health economies - if the opportunities identified recently for improvements in the efficiency of healthcare are to be realised. The Sun features Howard’s Way weight loss storyThe Sun newspaper has featured Paul Morris, 38, who lost six stones in weight in just over three months, thanks to the Howard’s Way very low calorie diet (VLCD). Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San FranciscoPARIS - Novexel, a specialty pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its pipeline will be the subject of 16 posters and one slide presentation at the 49th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The ICAAC meeting, which is taking place in San Francisco, California, September 12-15 2009, is the leading global conference on anti-microbial agents globally with over 10,000 participants. Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer PainLISBON, Portugal - - Head to Head Study Confirms Superiority of the New Intranasal Treatment for Breakthrough Cancer Pain Over OTFC New Data From CLARITY Study on Disease Activity in MS Patients who Received Cladribine Tablets Presented at 25th ECTRIMS CongressDÜSSELDORF, Germany and GENEVA - - Post-hoc Analysis From CLARITY Study Show That Short-Course Oral Treatment With Cladribine Tablets Significantly Increased the Proportion of Patients who had Absence of Disease Activity Compared With Placebo ThromboGenics is Shortlisted for “Biotech Company of the Year” and “Licensing Deal of the Year” at Scrip Awards 2009LEUVEN, Belgium - - ThromboGenics’ Significant Achievements Over the Last Year are Recognised in Nominations |
